SCANLUX-300 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Scanlux-300, and when can generic versions of Scanlux-300 launch?
Scanlux-300 is a drug marketed by Sanochemia Corp Usa and is included in one NDA.
The generic ingredient in SCANLUX-300 is iopamidol. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iopamidol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Scanlux-300
A generic version of SCANLUX-300 was approved as iopamidol by HAINAN POLY on February 27th, 2023.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SCANLUX-300?
- What are the global sales for SCANLUX-300?
- What is Average Wholesale Price for SCANLUX-300?
Summary for SCANLUX-300
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Clinical Trials: | 2 |
| Patent Applications: | 3,591 |
| DailyMed Link: | SCANLUX-300 at DailyMed |
Recent Clinical Trials for SCANLUX-300
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| QED Therapeutics, Inc. | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
| Stanford University | Phase 1 |
US Patents and Regulatory Information for SCANLUX-300
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanochemia Corp Usa | SCANLUX-300 | iopamidol | INJECTABLE;INJECTION | 090394-001 | Jun 18, 2010 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
